>Mercado de transfección en Oriente Medio y África, por tipo (transfección transitoria, transfección estable), métodos (métodos no virales, métodos virales), métodos de transfección CRISPR (métodos no virales, métodos virales), productos (reactivos y kits, instrumentos, software), organismo (células de mamíferos, plantas, hongos, virus, bacterias), tipos de moléculas (ADN plasmídico, ARN interferente pequeño (siRNA), proteínas, oligonucleótidos de ADN, complejos de ribonucleoproteína (RNP), otros), aplicación (aplicación in vitro, aplicación in vivo, bioproducción, otros), etapa (investigación, preclínica, fases clínicas, comercial), usuario final (biofarmacia, organizaciones de investigación por contrato (CRO), organización de fabricación por contrato/organización de desarrollo y fabricación por contrato (CMO/CDMO), academia, hospitales, laboratorios clínicos, otros), canal de distribución (licitación directa, ventas minoristas, otros), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto, resto de Oriente Medio y África: tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de transfección en Oriente Medio y África
Se espera que el mercado de transfección de Oriente Medio y África gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 8,0% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 33,81 millones para 2028. La creciente demanda de genes quiméricos y el aumento de la incidencia de enfermedades crónicas son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
La transfección implica la introducción de ácidos nucleicos en células eucariotas mediante métodos virales y no virales. El método de transfección puede superar el desafío asociado con la transferencia de la membrana cargada negativamente. Un producto químico como el fosfato de calcio y el dietilaminoetil (DEAE)-dextrano o reactivos catiónicos basados en lípidos reaccionan con la capa externa de ADN. Neutralizan la carga negativa general, además imparten la cantidad positiva a la molécula y, por lo tanto, permiten la administración de ADN. Los métodos físicos como la electroporación crean poros diminutos en la membrana celular mediante la aplicación de voltaje eléctrico, lo que permite la entrada de ADN directamente en el citoplasma. El DEAE-dextrano se utiliza para la transfección transitoria; sin embargo, la lipofección puede lograr una transfección estable y, por lo tanto, puede usarse para la expresión de proteínas a largo plazo. La transfección mediada por fosfato de calcio también se puede utilizar para la transfección estable. El método viral de transfección logra una alta eficiencia de transfección y se utiliza para varias fases del desarrollo de productos biofarmacéuticos.
El aumento de la prevalencia de enfermedades crónicas está actuando como un motor para el crecimiento del mercado de transfección. El alto costo de los instrumentos actúa como una restricción para el crecimiento del mercado de transfección. La exploración de mercados emergentes está actuando como una oportunidad para el crecimiento del mercado de transfección. El largo procedimiento de aprobación actúa como un desafío para el crecimiento del mercado de transfección.
El informe de mercado de transfección proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado , aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de transfección en Oriente Medio y África
El mercado de transfección está segmentado en función del tipo, los métodos, los métodos de transfección CRISPR, los productos, el organismo, los tipos de moléculas, la aplicación, la etapa, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- Según el tipo, el mercado de transfección se segmenta en transfección transitoria y transfección estable. En 2021, el segmento de transfección transitoria es el que predomina, ya que este método obtiene resultados de transfección en 3 a 7 días con altas tasas de eficiencia de transfección.
- En función de los métodos, el mercado de transfección se segmenta en métodos no virales y métodos virales . En 2021, el segmento de métodos no virales domina en todos los tipos de transfección, incluida la transfección CRISPR (repeticiones palindrómicas cortas agrupadas y regularmente interespaciadas), ya que estos métodos brindan una alta eficiencia de transfección y superan las posibilidades de infecciones inducidas por métodos de transfección viral.
- Sobre la base de los métodos de transfección CRISPR, el mercado de la transfección se segmenta en métodos no virales y métodos virales. En 2021, el segmento de métodos no virales domina la transfección CRISPR (repeticiones palindrómicas cortas agrupadas y regularmente interespaciadas), ya que permite la administración eficiente de secuencias CRISPR a líneas celulares específicas.
- En función de los productos, el mercado de transfección se segmenta en reactivos y kits, instrumentos y software. En 2021, el segmento de reactivos y kits es dominante, ya que se utilizan para mejorar la eficacia del proceso de transfección en varios experimentos genéticos.
- En función del organismo, el mercado de transfección se segmenta en células de mamíferos, plantas, hongos, virus y bacterias . En 2021, el segmento de células de mamíferos domina, ya que las células de mamíferos se utilizan ampliamente para la producción de anticuerpos monoclonales, proteínas, uroquinasa, hormona estimulante del folículo y otros productos en comparación con otros tipos de líneas celulares.
- On the basis of types of molecule, the transfection market is segmented into plasmid DNA, small interfering RNA (siRNA), proteins, DNA oligonucleotides, ribonucleoprotein complexes (RNPs) and others. In 2021, plasmid DNA segment is dominating as large number of transfection technologies have initially been developed for transfer of plasmid DNA into cells.
- On the basis of application, the transfection market is segmented into in vitro application, in vivo application, bioproduction and others. In 2021, in vitro application segment is dominating as it provides with the delivery of cargo nucleic acid molecules into cultured cells which has a crucial role in research as well as for commercial production of molecules.
- On the basis of stage, the transfection market is segmented into research, preclinical, clinical phases and commercial. In 2021, research segment is dominating due to increasing demand for gene expression across synthetic biology industry and other applications.
- On the basis of end user, the transfection market is segmented into biopharma, contract research organizations (CROs), contract manufacturing organization/contract development and manufacturing organization (CMOs/CDMOs), academia, hospitals, clinical labs and others. In 2021, biopharma segment hold the largest market share because of the increasing demand to improve efficiency & speed for production of desired cell lines.
- On the basis of distribution channel, the transfection market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is dominating as it is the primary source of procurement across different end users.
Middle East and Africa Transfection Market Country Level Analysis
The transfection market is analyzed and market size information is provided on the basis of country, type, methods, CRISPR transfection methods, products, organism, types of molecule, application, stage, end user and distribution channel as referenced above.
The countries covered in the Middle East and Africa transfection market report are report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, Rest of Middle East & Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are focused on utilization of biopharmaceuticals in the production of proteins and also using best therapeutic options for treatment of increasing chronic diseases. South Africa is dominating in Middle East and Africa due to increasing focus on stable cell line generation and virus production.
The country section of the transfection market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Surging Levels of Investment and Growing Demand of Chimeric Genes are boosting the Market Growth of Transfection
Transfection market also provides you with detailed market analysis for every country growth in transfection industry with transfection drugs sales, impact of advancement in the transfection technology and changes in regulatory scenarios with their support for the transfection market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Transfection Market Share Analysis
Middle East and Africa transfection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Middle East and Africa transfection market.
The major companies which are dealing in the Middle East and Africa transfection market are Mirus Bio LLC., Promega Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Cytiva, Thermofisher Scientific Inc., QIAGEN, OriGene Technologies, Inc. and SignaGen Laboratories among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the transfection market.
For instance,
- In November 2020, Thermofisher Scientific Inc. collaborated with Northeastern University to strengthen the biopharmaceutical industry's innovation and capabilities and gene and cell therapies. The company is continuously engaged in manufacturing innovative and advanced reagents and techniques to deliver sensitivity and accuracy to the ongoing experiments and drug development. This collaboration thus allowed the company to drive the growth of valuable and highly efficient reagents and tools utilized in the transfection procedure.
- En julio de 2019, Mirus Bio LLC lanzó un nuevo producto de calidad probada, el reactivo de transfección TransIT-VirusGEN SELECT, indicado para la administración eficiente de ADN con el fin de producir vectores virales a gran escala y de alto título. Este reactivo tiene la capacidad de mejorar la administración de ADN del vector de empaquetado y transferencia a los tipos de células HEK 293 adherentes y suspensiones de ADN. El lanzamiento de este producto mejoró la cartera de productos de la empresa e impulsó sus ingresos.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de transfección, lo que también proporciona el beneficio para que la organización mejore su oferta de transfección.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 TOTAL ADDRESSABLE MARKET
4.1.1 BY METHOD/MODALITY
4.1.2 BY END USER
4.1.3 BY APPLICATION
4.1.4 BY STAGE
4.2 EARLY AND LATE STAGE CELL LINE DEVELOPMENT FOR BIOPHARMA AND VIRAL VECTOR PRODUCTION FOR GENE THERAPY
4.2.1 THE LIST OF APPROVED ANTIBODIES PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS AND LIST OF SELECTABLE MARKERS USED IN MAMMALIAN EXPRESSION VECTORS
5 REGULATORY FRAMEWORK
5.1 EUROPEAN UNION REGULATORY SCENARIO
5.2 U.S. REGULATORY SCENARIO
5.3 JAPAN REGULATORY SCENARIO
5.4 CHINA REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS
6.1.3 GROWING DEMAND OF CHIMERIC GENES
6.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH
6.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TRANSFECTION PRODUCTS
6.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS
6.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE
6.3 OPPORTUNITIES
6.3.1 EXPLORATION OF EMERGING MARKET
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.3 INCREASING GOVERNMENT SUPPORT
6.3.4 SURGING LEVEL OF INVESTMENT
6.4 CHALLENGES
6.4.1 LONG APPROVAL PROCEDURE
6.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS ASSOCIATED TRANSFECTION
6.4.3 LACK OF TRAINED PROFESSIONALS
7 COVID-19 IMPACT OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN HEALTHCARE INDUSTRY
7.1 OVERVIEW
7.2 IMPACT ON THE PRICE
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC INITIATIVE BY MANUFACTURERS
7.6 CONCLUSION
8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE
8.1 OVERVIEW
8.2 TRANSIENT TRANSFECTION
8.2.1 BY STAGE
8.2.1.1 RESEARCH
8.2.1.2 PRECLINICAL
8.2.1.3 CLINICAL PHASES
8.2.1.4 COMMERCIAL
8.2.2 BY PRODUCT
8.2.2.1 REAGENT & KITS
8.2.2.2 INSTRUMENTS
8.2.2.3 SOFTWARE
8.3 STABLE TRANSECTION
8.3.1 BY STAGE
8.3.1.1 RESEARCH
8.3.1.2 PRECLINICAL
8.3.1.3 CLINICAL PHASES
8.3.1.4 COMMERCIAL
8.3.2 BY PRODUCT
8.3.2.1 REAGENT & KITS
8.3.2.2 INSTRUMENTS
8.3.2.3 SOFTWARE
9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS
9.1 2.1 OVERVIEW
9.2 NON- VIRAL METHODS
9.2.1 CHEMICAL
9.2.1.1 Lipofection Method
9.2.1.2 Calcium Phosphate Precipitation Method
9.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
9.2.1.4 Others
9.2.2 PHYSICAL
9.2.2.1 Electroporation
9.2.2.2 Direct Microinjection
9.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
9.2.2.4 Magnetofection
9.2.2.5 Sonoporation
9.2.2.6 Others
9.3 VIRAL METHODS
9.3.1 RETROVIRUS TRANSFECTION
9.3.2 ADENOVIRUS TRANSFECTION
9.3.3 LENTIVIRUS TRANSFECTION
9.3.4 OTHERS
10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS
10.1 OVERVIEW
10.2 NON- VIRAL METHODS
10.2.1 CHEMICAL
10.2.1.1 Lipofection Method
10.2.1.2 Calcium Phosphate Precipitation Method
10.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
10.2.1.4 Others
10.2.2 PHYSICAL
10.2.2.1 Electroporation
10.2.2.2 Direct Microinjection
10.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
10.2.2.4 Magnetofection
10.2.2.5 Sonoporation
10.2.2.6 Others
10.3 VIRAL METHODS
10.3.1 RETROVIRUS TRANSFECTION
10.3.2 ADENOVIRUS TRANSFECTION
10.3.3 LENTIVIRUS TRANSFECTION
10.3.4 OTHERS
11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY PRODUCTS
11.1 OVERVIEW
11.2 REAGENTS & KITS
11.2.1 CATIONIC LIPIDS
11.2.1.1 Liposomal Reagents
11.2.1.1.1 L-Dioleoyl Phosphatidylethanolamine (DOPE)
11.2.1.1.2 DOTAP [1,2-Dioleoyloxy-3-Trimethylammonium Propane]
11.2.1.1.3 DOTMA [N-[1(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethylammonium Chloride]
11.2.1.1.4 Others
11.2.1.2 Non-Liposomal Reagents
11.2.1.2.1 DNA Transfection Reagent
11.2.1.2.2 siRNA Transfection Reagent
11.2.1.2.3 Others
11.2.2 CATIONIC POLYMER
11.2.2.1 DEAE-Dextran
11.2.2.2 Polybrene
11.2.2.3 Polyethyleneimine
11.2.2.4 Dendrimers
11.2.2.5 Others
11.2.3 NANOPARTICLES
11.2.3.1 Systemic Intravenous Injection
11.2.3.2 Direct Intratumoral Injection
11.2.4 KITS
11.2.4.1 Transporter Transfection Reagent
11.2.4.2 GMP Transfection Reagent
11.2.4.3 Neon Electroporation
11.2.4.4 Cellfectin Ii Transfection Reagent
11.2.4.5 DMRIE-C Transfection Reagent
11.2.4.6 Lipofectamine Transfection Reagent
11.2.4.7 Lipofectin Transfection Reagent
11.2.4.8 Oligofectamine Transfection Reagent
11.2.4.9 Optifect Transfection Reagent
11.2.4.10 Cell Specific Transfection Reagent
11.2.4.11 Gene Gun Kit
11.2.4.12 Plasmid Transfection Reagent
11.2.4.13 Others
11.2.5 CUVETTE CHAMBER
11.2.6 OTHERS
11.3 INSTRUMENT
11.3.1 ELECTROPORATION SYSTEM
11.3.1.1 Neon Transfection System
11.3.1.2 Others
11.3.2 ELECTRO-CELL FUSION GENERATOR
11.3.3 ELECTRO-KINETIC TRANSFECTION SYSTEM
11.3.4 HEPTA SYSTEM
11.3.5 TUBING PREP STATION
11.3.6 RT-PCR
11.3.7 GUN SYSTEM
11.3.8 MICROPLATE READER
11.3.9 SONOPORATION SYSTEM
11.3.10 MICROSCOPES
11.3.11 OTHERS
12 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY ORGANISM
12.1 OVERVIEW
12.2 MAMMALIAN CELLS
12.3 PLANTS
12.4 FUNGI
12.5 VIRUS
12.6 BACTERIA
13 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE
13.1 OVERVIEW
13.2 PLASMID DNA
13.3 SMALL INTERFERING RNA (SIRNA)
13.4 PROTEINS
13.5 DNA OLIGONUCLEOTIDES
13.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)
13.7 OTHERS
14 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 BY TYPE
14.2.1 IN VITRO APPLICATION
14.2.1.1 Gene Expression
14.2.1.2 RNA Interference
14.2.2 IN VIVO APPLICATION
14.2.2.1 Gene Therapy
14.2.2.2 Cellular-Based Therapy
14.2.3 BIOPRODUCTION
14.2.3.1 Antibody/Protein Production
14.2.3.2 Virus Production
14.2.4 OTHERS
14.3 BY INDUSTRY
14.3.1 SYNTHETIC BIOLOGY
14.3.1.1 Biopharma
14.3.1.2 Monoclonal Antibodies (mAbs)
14.3.1.3 Recombinant Proteins
14.3.1.4 Biofuels
14.3.1.5 Cell Line Development
14.3.1.6 Flavors & Fragrances
14.3.1.7 Enzyme Engineering & Production
14.3.1.8 Specialty Chemicals
14.3.2 AGRICULTURE
14.3.3 OTHERS
15 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY STAGES
15.1 OVERVIEW
15.2 RESEARCH
15.3 PRECLINICAL
15.4 CLINICAL PHASES
15.5 COMMERCIAL
16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY END USER
16.1 OVERVIEW
16.2 BIOPHARMA
16.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
16.4 CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS)
16.5 ACADEMIA
16.6 HOSPITALS
16.7 CLINICAL LABS
16.8 OTHERS
17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.4 OTHERS
18 MIDDLE EAST AND AFRICA TRASNFECTION MARKET, BY GEOGRAPHY
18.1 MIDDLE EAST & AFRICA
18.1.1 SOUTH AFRICA
18.1.2 SAUDI ARABIA
18.1.3 UAE
18.1.4 ISRAEL
18.1.5 EGYPT
18.1.6 REST OF MIDDLE EAST & AFRICA
19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 THERMOFISHER SCIENTIFIC INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMAPYN SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 QIAGEN
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 PROMEGA CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 COMPANY SHARE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 TAKARA BIO INC.
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 BIO-RAD LABORATORIES, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANANLYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 LONZA
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANANLYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 CYTIVA
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 ALTOGEN BIOSYSTEMS
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 AMYRIS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 AUTOLUS
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 CODEXIS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 CONAGEN, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 PRODUCT PORTFOLIO
21.16.3 RECENT DEVELOPMENTS
21.17 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANANLYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 GENLANTIS INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 PRODUCT PORTFOLIO
21.18.3 RECENT DEVELOPMENTS
21.19 GENO TECHNOLOGY INC., USA
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 GINKGO BIOWORKS
21.20.1 COMPANY SNAPSHOT
21.20.2 PRODUCT PORTFOLIO
21.20.3 RECENT DEVELOPMENTS
21.21 IMPOSSIBLE FOODS INC.
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENTS
21.22 MAXCYTE, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENTS
21.23 MERCK KGAA
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 MIRUS BIO LLC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENTS
21.25 ORIGENE TECHNOLOGIES, INC.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENTS
21.26 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)
21.26.1 COMPANY SNAPSHOT
21.26.2 REVENUE ANANLYSIS
21.26.3 PRODUCT PORTFOLIO
21.26.4 RECENT DEVELOPMENTS
21.27 POLYPLUS TRANSFECTION
21.27.1 COMPANY SNAPSHOT
21.27.2 PRODUCT PORTFOLIO
21.27.3 RECENT DEVELOPMENTS
21.28 POSEIDA THERAPEUTICS, INC.
21.28.1 COMPANY SNAPSHOT
21.28.2 PRODUCT PORTFOLIO
21.28.3 RECENT DEVELOPMENTS
21.29 R&D SYSTEMS, INC.
21.29.1 COMPANY SNAPSHOT
21.29.2 PRODUCT PORTFOLIO
21.29.3 RECENT DEVELOPMENT
21.3 SBS GENETECH
21.30.1 COMPANY SNAPSHOT
21.30.2 PRODUCT PORTFOLIO
21.30.3 RECENT DEVELOPMENTS
21.31 SIGNAGEN LABORATORIES
21.31.1 COMPANY SNAPSHOT
21.31.2 PRODUCT PORTFOLIO
21.31.3 RECENT DEVELOPMENTS
21.32 TWIST BIOSCIENCE
21.32.1 COMPANY SNAPSHOT
21.32.2 REVENUE ANALYSIS
21.32.3 PRODUCT PORTFOLIO
21.32.4 RECENT DEVELOPMENTS
21.33 VERVE THERAPEUTICS, INC.
21.33.1 COMPANY SNAPSHOT
21.33.2 PRODUCT PORTFOLIO
21.33.3 RECENT DEVELOPMENTS
21.34 ZYMERGEN INC.
21.34.1 COMPANY SNAPSHOT
21.34.2 PRODUCT PORTFOLIO
21.34.3 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 LIST OF APPROVED ANTIBODIES PRODUCED IN CHO CELLS
TABLE 2 EU DIRECTIVES AND REGULATIONS RELATED TO CLINICAL TRIALS INVOLVING GTMPS
TABLE 3 GOVERNMENT ENTITIES THAT ARE IN CHARGE OF TYPE 2 USES
TABLE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA SOFTWARE BY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA MAMMALIAN CELLS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PLANTS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA FUNGI IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA VIRUS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA PLASMID DNA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA PROTEINS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DNA OLIGONUCLEOTIDES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA BIOPRODUCTION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA AGRICULTURE IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA RESEARCH IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA PRE-CLINICAL IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA CLINICAL PHASES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA COMMERCIAL IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA BIOPHARMA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA ACADEMIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA CLINICAL LABS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA DIRECT TENDER IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA RETAIL SALES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 81 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 86 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 87 MIDDLE EAST & AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 90 MIDDLE EAST & AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 92 MIDDLE EAST & AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 93 MIDDLE EAST & AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 96 MIDDLE EAST & AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 99 MIDDLE EAST & AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 105 MIDDLE EAST & AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 106 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 MIDDLE EAST & AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 117 SOUTH AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 118 SOUTH AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 SOUTH AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 SOUTH AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 SOUTH AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 SOUTH AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 123 SOUTH AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 124 SOUTH AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 125 SOUTH AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 126 SOUTH AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 127 SOUTH AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 128 SOUTH AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 129 SOUTH AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 130 SOUTH AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 131 SOUTH AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 132 SOUTH AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 133 SOUTH AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 134 SOUTH AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 135 SOUTH AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 136 SOUTH AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 137 SOUTH AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 138 SOUTH AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 139 SOUTH AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 140 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 141 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 142 SOUTH AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 143 SOUTH AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 144 SOUTH AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 145 SOUTH AFRICA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 SOUTH AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 SOUTH AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 SOUTH AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 SOUTH AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 SOUTH AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 SOUTH AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 152 SOUTH AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 SOUTH AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 SAUDI ARABIA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 155 SAUDI ARABIA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 SAUDI ARABIA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 SAUDI ARABIA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 SAUDI ARABIA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 SAUDI ARABIA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 160 SAUDI ARABIA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 161 SAUDI ARABIA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 162 SAUDI ARABIA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 163 SAUDI ARABIA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 164 SAUDI ARABIA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 165 SAUDI ARABIA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 166 SAUDI ARABIA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 167 SAUDI ARABIA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 168 SAUDI ARABIA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 169 SAUDI ARABIA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 170 SAUDI ARABIA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 171 SAUDI ARABIA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 172 SAUDI ARABIA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 173 SAUDI ARABIA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 174 SAUDI ARABIA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 175 SAUDI ARABIA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 176 SAUDI ARABIA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 177 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 178 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 179 SAUDI ARABIA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 180 SAUDI ARABIA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 181 SAUDI ARABIA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 182 SAUDI ARABIA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 SAUDI ARABIA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 SAUDI ARABIA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 SAUDI ARABIA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 SAUDI ARABIA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 SAUDI ARABIA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 SAUDI ARABIA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 189 SAUDI ARABIA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 190 SAUDI ARABIA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 191 UAE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 192 UAE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 UAE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 UAE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 UAE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 UAE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 197 UAE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 198 UAE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 199 UAE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 200 UAE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 201 UAE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 202 UAE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 203 UAE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 204 UAE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 205 UAE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 206 UAE TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 207 UAE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 208 UAE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 209 UAE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 210 UAE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 211 UAE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 212 UAE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 213 UAE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 214 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 215 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 216 UAE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 217 UAE TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 218 UAE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 219 UAE TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 UAE IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 UAE IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 UAE BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 UAE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 UAE SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 225 UAE TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 226 UAE TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 227 UAE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 228 ISRAEL TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 229 ISRAEL TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 ISRAEL TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 ISRAEL STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 232 ISRAEL STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 233 ISRAEL TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 234 ISRAEL NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 235 ISRAEL CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 236 ISRAEL PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 237 ISRAEL VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 238 ISRAEL CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 239 ISRAEL NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 240 ISRAEL CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 241 ISRAEL PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 242 ISRAEL VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 243 ISRAEL TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 244 ISRAEL REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 245 ISRAEL CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 246 ISRAEL LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 247 ISRAEL NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 248 ISRAEL CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 249 ISRAEL KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 250 ISRAEL NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 251 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 252 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 253 ISRAEL ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 254 ISRAEL TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 255 ISRAEL TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 256 ISRAEL TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 257 ISRAEL IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 258 ISRAEL IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 259 ISRAEL BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 260 ISRAEL TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 261 ISRAEL SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 262 ISRAEL TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 263 ISRAEL TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 264 ISRAEL TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 265 EGYPT TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 266 EGYPT TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 EGYPT TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 EGYPT STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 EGYPT STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 EGYPT TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 271 EGYPT NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 272 EGYPT CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 273 EGYPT PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 274 EGYPT VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 275 EGYPT CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 276 EGYPT NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 277 EGYPT CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 278 EGYPT PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 279 EGYPT VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 280 EGYPT TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 281 EGYPT REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 282 EGYPT CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 283 EGYPT LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 284 EGYPT NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 285 EGYPT CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 286 EGYPT KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 287 EGYPT NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 288 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 289 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 290 EGYPT ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 291 EGYPT TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 292 EGYPT TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 293 EGYPT TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 294 EGYPT IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 295 EGYPT IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 296 EGYPT BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 297 EGYPT TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 298 EGYPT SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 299 EGYPT TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 300 EGYPT TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 301 EGYPT TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 REST OF MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA TRANSFECTION MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION
FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN 2021 & 2028
FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET
FIGURE 16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 21 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 25 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020
FIGURE 29 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020
FIGURE 33 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020
FIGURE 37 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, CAGR (2021-2028)
FIGURE 39 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020
FIGURE 41 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 43 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020
FIGURE 45 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020-2028 (USD MILLION)
FIGURE 46 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, CAGR (2021-2028)
FIGURE 47 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, LIFELINE CURVE
FIGURE 48 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020
FIGURE 49 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 50 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 51 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 53 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 54 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 55 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 MIDDLE EAST & AFRICA TRANSFECTION MARKET: SNAPSHOT (2020)
FIGURE 57 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020)
FIGURE 58 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 59 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 60 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY TYPE (2021-2028)
FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
